We use our own cookies and third-party cookies to improve our services and analyse the browsing habits of our users. Continuing to browse our sites implies full acceptance of their use. You can change your cookie setting or get more information here

Lipopharma Therapeutics S.L.

Lipopharma Therapeutics S.L.

Description

Lipopharma is a pioneering clinical-stage biopharmaceutical company that focuses its activities on the discovery, design and clinical development of a new generation of medicines that act through the selective regulation of membrane lipids, a novel therapeutic strategy known as “Membrane-Lipid Therapy” (MLT). Lipopharma arose as an academic spin-off, founded to turn new scientific breakthroughs and discoveries made by scientists at the University of the Balearic Islands in Mallorca, Spain, into a new class of innovative lipid-regulator therapeutic agents that we believe have dramatic game-changing potential in the treatment of life-threatening conditions like cancer, Alzheimer's disease, inflammatory or metabolic diseases.

Pipeline

Product Type of product Therapeutic Area Indication Development Phase
LP561A1 Drug Oncología Cáncer Phase II / Clinical Validation
LP226A1 Drug SNC Enfermedades neurodegenerativas Pre-clinical Regulatory/ Preliminary validation
L204A1 Drug Enfermedades inflamatorias Inflamación No pre-clinical regulatory / R+D
LP10218 Drug Oncología Cáncer No pre-clinical regulatory / R+D
LP20104 Drug Oncología Cáncer No pre-clinical regulatory / R+D
LPA181 Drug SNC Lesión de Médula Espinal No pre-clinical regulatory / R+D
LPA205A1 Drug SNC Enfermedades neurodegenerativas No pre-clinical regulatory / R+D
LP30171 Drug Oncología y Metábolismo Cáncer y enfermedades metabólicas No pre-clinical regulatory / R+D

Patents

Product Type of product Therapeutic Area Indication Development Phase
PCT/ES02/00475 Patent Oncología y enfermedades cardiovasculares Cáncer e hipertensión No pre-clinical regulatory / R+D
P200803480 Patent Varias No específica No pre-clinical regulatory / R+D
PCT/ES2009/070252 Patent SNC Lesión de Médula Espinal No pre-clinical regulatory / R+D
PCT/ES2010/070153 Patent Varias No específica No pre-clinical regulatory / R+D
PCT/ES2012/070697 Patent Varias No específica No pre-clinical regulatory / R+D

Services/Products

  • LP561A1 (2OHOA), Lipopharma’s lead R&D program, is an orally administered synthetic analogue of oleic acid that activates sphingomyelin synthase (SMS) which results in a specific “normalization” of the altered membrane lipid composition of cancer cells. Therefore, it regulates the localization and activity of a number of key peripheral signal transduction proteins, normalizing the activity of critical signalling pathways for the proliferation of cancer cells (Ras/MAPK/PI3k/Akt, cyclin/CDK), inducing stop of cell proliferation and selective death of cancer cells by autophagy (in glioma). The European Medicines Agency designated 2-OHOA as an orphan medicinal product for the treatment of glioma in October 2011 (EU/3/11/916). A phase I/IIa clinical trial of Minerval in Adult Patients with Advanced Solid Tumours including Malignant Glioma (MIN-001-1203) is currently underway and recruiting participants since May 2013. The preliminary results of the adult trial are promising, with clinical responses confirmed in several patients, including advanced glioblastoma patients, while no drug-related toxicities have been found, other than anticipated Gastrointestinal (GI) effects at high doses.
  • LP226A1 is a polyunsaturated fatty acid derivative that was designed with the aim of restoring the membrane lipid structure to prevent the molecular and cellular alterations observed in AD patients.
  • LP204A1 is a polyunsaturated fatty acid derivative that produces a remarkable anti-inflammatory effect in a LPS-challenged mouse model of inflammation, acting through COX1 and COX2
  • Lipopharma currently investigates the therapeutic applications of new compounds designed on the basis of our innovative Membrane-Lipid Therapy (MLT) know-how: LPA181, LP205A1, LP10218, LP20104 and LP30171.

Tecnology

Membrane Lipid Therapy (MLT). An innovative technology that focuses on lipids of cell membranes.

Market/ Developement areas

  • Oncology. Drug development for the treatment of cancers among them glioma, lung, pancreatic and prostate cancer.
  • Neurodegeneration. Development of drugs for the treatment of neurodegenerative diseases with special emphasis on Alzheimer's disease.
  • Spinal Cord. Drug development to improve mobility in spinal cord injuries.
  • Inflammation. Development of drugs for the treatment of inflammatory and autoimmune diseases.
  • Development of cardio-food and nutraceutical supplements.

Share

Download sheet